title: Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels.
abstract: Many HIV-1-infected patients on suppressive antiretroviral therapy (ART) have transiently elevated HIV RNA levels. The clinical significance of these viral blips is uncertain. We have determined the incidence of blips and investigated important associations in the Swedish HIV-cohort.
  
  
  
  HIV-1-infected ART naïve adults who commenced ART 2007-2013 were retrospectively included. Viral blips were defined as a transient viral load between 50 and 500 copies/mL Subjects not suppressed after six months on ART were excluded.
  
  
  
  Viral blips were found in 76/735 included subjects (10.3 %) and in 90/4449 samples (2.0 %). Median blip viral load was 76 copies/mL (range 56-138). Median follow-up time was 170 weeks (range 97-240). Baseline viral load was higher in subjects with viral blips (median log10 4.85 copies/mL) compared with subjects without blips (median log10 4.55 copies/mL) (p < 0.01). There was a significant association between viral blips and risk for subsequent virological failure (p < 0.001).
  
  
  
  The Swedish national HIV-cohort has a low incidence of viral blips (10 %). Blips were associated with high baseline viral load and an increased risk of subsequent virological failure.
authors.affiliation: Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 413 90, Gothenburg, Sweden. erik.sorstedt@vgregion.se.
authors.forename: Erik
authors.identifier: 0000-0001-6966-7485
authors.initials: E
authors.lastname: Sörstedt
authors.affiliation: Department of Mathematical Sciences, Chalmers University of Technology, 412 58, Gothenburg, Sweden.
authors.forename: Staffan
authors.initials: S
authors.lastname: Nilsson
authors.affiliation: Department of Infectious Diseases, Venhälsan-Södersjukhuset, 118 83, Stockholm, Sweden.
authors.forename: Anders
authors.initials: A
authors.lastname: Blaxhult
authors.affiliation: Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 413 90, Gothenburg, Sweden.
authors.forename: Magnus
authors.initials: M
authors.lastname: Gisslén
authors.affiliation: Department of Infectious Diseases, Malmö University Hospital, 205 02, Malmö, Sweden.
authors.forename: Leo
authors.initials: L
authors.lastname: Flamholc
authors.affiliation: Department of Infectious Diseases, Karolinska Institute, Karolinska University Hospital, 141 86, Stockholm, Sweden.|Department of Clinical Microbiology, Karolinska Institute, Karolinska University Hospital, 141 86, Stockholm, Sweden.
authors.forename: Anders
authors.initials: A
authors.lastname: Sönnerborg
authors.affiliation: Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 413 90, Gothenburg, Sweden.
authors.forename: Aylin
authors.initials: A
authors.lastname: Yilmaz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018450:Disease Progression; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood*; D012189:Retrospective Studies; D013548:Sweden; D019562:Viral Load; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral
keywords: Antiretroviral therapy; HIV-1; Transient viremia; Viral blip